
Innovative Industrial Properties remains a 'Strong Buy,' supported by a robust balance sheet and regulatory catalysts in the cannabis sector. IIPR's low leverage at 2.1x debt/EBITDA offers downside protection amid ongoing tenant volatility and sector concentration risks. Rescheduling of medical cannabis has improved tenant credit, but the main catalyst remains potential rescheduling of recreational sales.










